Skip to main content

Table 1 Key model inputs for the cost-effectiveness analysis

From: Offering a lifestyle intervention to women of premenopausal age as primary prevention for cardiovascular disease? – assessing its cost-effectiveness

Variable

Definition

Basecase value

Reference

Sensitivity analysis

Female

DSA

PSAa

Utility

 u_norm

Age 16–19

0.87

Hawthorne et al. 2013 [25]

 

0.17

 

Age 20–29

0.84

 

0.2

 

Age 30–39

0.84

 

0.21

 

Age 40–49

0.81

 

0.22

 

Age 50–59

0.8

 

0.23

 

Age 60–69

0.79

 

0.22

 

Age 70–79

0.76

 

0.24

 

Age 80–85

0.68

 

0.26

 u_stroke_IS

   

0–1

 
 

mRS 0

0.63

Sturm et al. 2002 [28]

  
 

mRS 1

0.63

  
 

mRS 2

0.4

  
 

mRS 3

0.18

  
 

mRS 4

0.06

  
 

mRS 5

0.02

  

 u_TIA

Utility value post TIA

0.63

Sturm et al. 2002 [28]

  

 u_stroke_HE

Utility value post a haemorrhagic stroke

0.3

Shin et al. 1997 [29]

0–0.6

 

 u_MI

Utility value post a MI

0.87

Tsevat et al. 1993 [30]

0.80–0.95

 

 u_CHF

Utility value post CHF

0.67

Pandor et al. 2013 [31]

  

 u_PVD

Utility value post PVD

0.79

Itoga et al. 2018 [32]

  

 u_otherCHDb

Utility value post other CHD

0.665

Calculated

  

 u_postCVD

Utility value post CVD

0.626

   

Costs

Acute phase

  c_MI

cost of hospitalisation for a myocardial infarction

$ 8944

NHCDC 2015–16 cost report

 

894

  c_UA

cost of hospitalisation for an unstable angina

$ 6077

NHCDC 2015–16 cost report

 

608

  c_otherCVD

cost of hospitalisation for other CVD

$ 9796

NHCDC 2015–16 cost report

 

980

  c_stroke_IS

cost of hospitalisation for an ischaemic stroke

$ 10,712

NHCDC 2015–16 cost report

5733-22,245

1071

  c_stroke_HA

cost of hospitalisation for a haemorrhagic stroke

$ 15,563

NHCDC 2015–16 cost report

6116-22,245

1556

  c_TIA

cost of hospitalisation for a TIA

$ 5172

NHCDC 2015–16 cost report

3339-7005

 

  c_PVD

cost of hospitalisation for a peripheral vascular disease

$ 6241

NHCDC 2015–16 cost report

 

  c_CHD

cost of hospitalisation for a congestive heart failure

$ 7003

NHCDC 2015–16 cost report

3037-12,423

700

  c_CVD_death_other

cost of other CVD-related death

$ 8688

average

  

Long-term management

  

  c_mgmt_MI

cost of management post MI

$ 4302

Turkstra et al. 2013 [33]

 

430

  c_mgmt_UA

cost of management post UA

$ 4302

  

  c_mgmt_otherCVD

cost of management post otherCVD

$ 4667

average

  

  c_mgmt_stroke

cost of management post stroke

$ 6410

NHCDC 2015–16 cost report; Cobiac et al. 2012 [34]

 

641

  c_mgmt_TIA

cost of management post TIA

$ 1431

mRS0

  

  c_mgmt_PVD

cost of management post PVD

$ 5062

Itoga et al. 2018 [32]

  
 

mild case (intermittent claudication), outpatient visit every per 3 months

$ 150

MBS 23

  
 

severe case (critical limb ischaemia), outpatient visit every month, 30 min nurse time every 2 weeks

$ 1990

MBS 104 & MBS 82210

  
 

amputated case (GBP 23,502/AUD 41902 per year)

$ 41,902

   

  c_mgmt_CHD

cost of management post CHD

$ 6494

Maru et al. 2018 [35]

 

649

  c_mgmt_postCVD

the average cost of post CVD management

$ 4667

Assumption

  

  c_intervention

group physical activity training

$ 31.63

MBS 10953

  
 

individual dietitian

$ 60.60

MBS 10954

  
 

group dietitian

$ 80.80

MBS 81105

  
 

text reminder

$ 1.00

Gao et al. 2018 [36]

  
  1. aSD and the mean from the base case value were used to define beta distribution for utility variables or gamma distribution for cost variables in the probabilistic sensitivity analyses, according to the empirical evidence
  2. baverage across stroke, MI, CHF, and PVD